## CONTENTS

Preface ............................................................................................................................ v
Contributors ................................................................................................................... xi
Color Illustrations ......................................................................................................... xv

### I  CANCER DRUG DEVELOPMENT
1 Cancer Drug Development: *Challenges in a Competitive Market*
   *Barry Greene and Michael Kauffman* ............................................................... 3

### II  CHEMISTRY AND CELL BIOLOGY OF THE PROTEASOME
2 Introduction to the Proteasome and Its Inhibitors:
   *Biochemistry and Cell Biology*
   *Alfred L. Goldberg* ............................................................................................. 17
3 Structures of the Yeast Proteasome Core Particle in Complex with Inhibitors
   *Michael Groll and Robert Huber* ................................................................. 39
4 Natural Product and Synthetic Proteasome Inhibitors
   *Kyung Bo Kim and Craig M. Crews* ............................................................... 47
5 Other Proteasome Inhibitors
   *Carlos García-Echeverría* ................................................................................. 65
6 The Proteasome in Cell-Cycle Regulation
   *Julian Adams* ..................................................................................................... 77
7 Proteasome Inhibition and Apoptosis
   *Simon A. Williams and David J. McConkey* .................................................... 85
8 The Proteasome and the COMPARE Algorithm
   *Susan L. Holbeck and Edward A. Sausville* .................................................... 99

### III  RATIONALE FOR PROTEASOME INHIBITORS IN CANCER
9 The Proteasome in Cancer Biology and Therapy
   *Frank Pajonk and William H. McBride* ........................................................ 111
10 Radiosensitization and Proteasome Inhibition
   *Carter Van Waes, John B. Sunwoo, William DeGraff, and James B. Mitchell* ................................................................. 123
11 Proteasome-Dependent Regulation of NF-kB Activation:
   *Molecular Targeting of Chemotherapy Resistance*
   *James C. Cusack, Jr.* ....................................................................................... 131
12 Bortezomib with Taxanes
   *Leonard Liebes, Bruce Ng, Yi-He Ling, and Roman Perez-Soler* ............... 145
13 Proteasome Inhibitor Therapy in a Brain Tumor Model
   *Jeffrey J. Olson, Geoffrey Bowers, and Zhaobin Zhang* .............................. 161
14 Anthracyclines and Bortezomib
   *Robert Z. Orlowski* ........................................................................................... 171
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>TNF-Related Apoptosis-Inducing Ligand (TRAIL): Combination with Proteasome Inhibition For Anticancer Therapy?</td>
<td>Thomas J. Sayers</td>
<td>181</td>
</tr>
<tr>
<td>16</td>
<td>Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin</td>
<td>Edward G. Mimnaugh and Leonard M. Neckers</td>
<td>193</td>
</tr>
<tr>
<td>17</td>
<td>The Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation</td>
<td>Marcus Groettrup, Rita de Giuli, and Gunter Schmidtke</td>
<td>207</td>
</tr>
<tr>
<td>18</td>
<td>Function(s) of the Ubiquitin–Proteasome System in Retrovirus Budding</td>
<td>Ulrich Schubert</td>
<td>217</td>
</tr>
<tr>
<td>IV</td>
<td><strong>Clinical Trials</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Preclinical Development of Bortezomib (VELCADE™): Rationale for Clinical Studies</td>
<td>Julian Adams, Peter J. Elliott, and Page Bouchard</td>
<td>233</td>
</tr>
<tr>
<td>20</td>
<td>Phase I Trials: Bortezomib Alone and in Combination with Standard Chemotherapies</td>
<td>Dixie-Lee W. Esseltine and David P. Schenke</td>
<td>271</td>
</tr>
<tr>
<td>21</td>
<td>Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy</td>
<td>Jeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher, Jeffrey Brown, George Mulligan, Jim Deeds, and James Stec</td>
<td>283</td>
</tr>
<tr>
<td>22</td>
<td>Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma</td>
<td>Kenneth C. Anderson</td>
<td>301</td>
</tr>
<tr>
<td></td>
<td>Index</td>
<td></td>
<td>307</td>
</tr>
</tbody>
</table>
Proteasome Inhibitors in Cancer Therapy
Adams, J. (Ed.)
2004, XV, 313 p., Hardcover
ISBN: 978-1-58829-250-6
A product of Humana Press